349 Oyster Point Boulevard
South San Francisco, CA 94080
650 938 6300
Industry: Diagnostics & Research
|Ms. Anne Wojcicki||Co-Founder, CEO, Pres & Director||59.28k||N/A||N/A|
|Ms. Kathy L. Hibbs Esq., J.D.||Chief Admin. Officer and Sec.||567.2k||340.28k||1964|
|Dr. Kenneth J. Hillan Ch.B., M.B.||Chief Therapeutics Officer||582.2k||N/A||1961|
|Mr. Joseph Selsavage||Interim CFO & Accounting Officer||N/A||N/A||1963|
|Dr. Joseph R. Arron M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Wade Walke||VP of Investor Relations||N/A||N/A||1966|
|Ms. Jacquie Cooke Haggarty J.D.||Gen. Counsel & Privacy Officer||N/A||N/A||N/A|
|Ms. Katie Watson||VP of Communications||N/A||N/A||1978|
|Mr. Jonathan Ward||Chief Marketing Officer||N/A||N/A||N/A|
|Ms. Savita Pillai||VP of People||N/A||N/A||N/A|
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
23andMe Holding Co.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 10; Compensation: 10.